Gayathri Pramil Menon
Research Subjects
Gayathri Pramil Menon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anirudh
Department of Internal Medicine All India Institute of Medical Sciences Bathinda India
2 shared publications - Anusree Chakraborty
M Abdur Rahim Medical College, Dinajpur, Bangladesh
2 shared publications - Pedro Vega Guillen2 shared publications
- Alsalt Al-Busaidi
School of Medicine, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, D02 YN77, Ireland
1 shared publication - Om Prakash Bhatta
Department of Internal Medicine Nova Hospital Dhangadhi Nepal
1 shared publication - Priyanka Sahajwani1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Advanced Gut & Microbiome Research
- Vol. 2026 (1)
Exosomal MicroRNAs in Pancreatic Ductal Adenocarcinoma: Mechanism of Proliferation, Diagnosis, Prognosis, and Treatment
Pancreatic cancer remains one of the deadliest malignancies worldwide, largely because it is often asymptomatic in its early stages and therefore diagnosed late, when curative treatment options are limited. In the United States, it accounts for approximately 3% of all cancers and about 8% of all cancer‐related deaths. Pancreatic ductal adenocarcinoma is the most common histologic subtype and continues to have a very poor prognosis, underscoring the urgent need for improved early detection strategies. Current diagnostic approaches, including magnetic resonance imaging (MRI) and contrast‐enhanced computed tomography (CT), are useful mainly in high‐risk populations, whereas emerging combinations such as ultrasound with MRI may broaden screening potential. In parallel, growing interest has focused on molecular diagnostics, particularly microRNAs (miRNAs), which regulate gene expression posttranscriptionally and have been implicated in pancreatic cancer biology. Although miRNA‐based approaches are promising for early diagnosis, prognosis, and treatment response assessment, most evidence remains derived from preclinical studies or small clinical cohorts and requires further validation before routine clinical use. This review examines the current evidence on the roles of miRNAs in the diagnosis, prognosis, and treatment of pancreatic cancer.
- 1 January 2026
- Published by Wiley in Advanced Gut & Microbiome Research
- Vol. 2026 (1)
Open AccessExosomal MicroRNAs in Pancreatic Ductal Adenocarcinoma: Mechanism of Proliferation, Diagnosis, Prognosis, and Treatment
Pancreatic cancer remains one of the deadliest malignancies worldwide, largely because it is often asymptomatic in its early stages and therefore diagnosed late, when curative treatment options are limited. In the United States, it accounts for approximately 3% of all cancers and about 8% of all cancer‐related deaths. Pancreatic ductal adenocarcinoma is the most common histologic subtype and continues to have a very poor prognosis, underscoring the urgent need for improved early detection strategies. Current diagnostic approaches, including magnetic resonance imaging (MRI) and contrast‐enhanced computed tomography (CT), are useful mainly in high‐risk populations, whereas emerging combinations such as ultrasound with MRI may broaden screening potential. In parallel, growing interest has focused on molecular diagnostics, particularly microRNAs (miRNAs), which regulate gene expression posttranscriptionally and have been implicated in pancreatic cancer biology. Although miRNA‐based approaches are promising for early diagnosis, prognosis, and treatment response assessment, most evidence remains derived from preclinical studies or small clinical cohorts and requires further validation before routine clinical use. This review examines the current evidence on the roles of miRNAs in the diagnosis, prognosis, and treatment of pancreatic cancer.
- Open Access
- 1 January 2025
- Published by Wiley in Advanced Gut & Microbiome Research
- Vol. 2025 (1)
Gut Microbiota and Gastric Cancer: The Immunoregulatory Mechanism and the Preventive Role of Microbiota‐Derived Short‐Chain Fatty Acids
Gastric cancer is still a major worldwide health problem, and its etiology is attributed to several factors, including the composition of the gut microbiota and its immunomodulatory functions. The present review discusses the complex interrelationship between the gut microbiota metabolites, especially short‐chain fatty acids (SCFAs) and the onset of gastric cancer. Dysbiosis of the gut microbiota, reduced diversity of microbial species, and increased relative abundance of certain bacterial taxa have been found to contribute to the progression of gastric cancer and its treatment. For instance, Helicobacter pylori is still considered a well‐recognized cause; nevertheless, other bacteria, such as Enterobacteriaceae and Prevotella , have emerged as putative gastric cancer causative agents in recent investigations. In addition, SCFAs, particularly butyrate, produced in the gut are known to modulate immune functions by enhancing the cytotoxic activity of CD8+ T cells and preventing gastric cancer, possibly via the GPR109A receptor. Although research on the cause–effect relationship between microbiota and gastric cancer is an emerging field, available data from human and animal studies suggest that the manipulation of the gut microbiota—through probiotics, diet, or specific treatments—may be useful in preventing and managing gastric cancer. This review discusses the role of gut microbiota and SCFAs in the diagnosis and therapy of gastric cancer, with a focus on their effective application in gastric cancer treatment.
- 1 January 2025
- Published by Wiley in Advanced Gut & Microbiome Research
- Vol. 2025 (1)
Open AccessGut Microbiota and Gastric Cancer: The Immunoregulatory Mechanism and the Preventive Role of Microbiota‐Derived Short‐Chain Fatty Acids
Gastric cancer is still a major worldwide health problem, and its etiology is attributed to several factors, including the composition of the gut microbiota and its immunomodulatory functions. The present review discusses the complex interrelationship between the gut microbiota metabolites, especially short‐chain fatty acids (SCFAs) and the onset of gastric cancer. Dysbiosis of the gut microbiota, reduced diversity of microbial species, and increased relative abundance of certain bacterial taxa have been found to contribute to the progression of gastric cancer and its treatment. For instance, Helicobacter pylori is still considered a well‐recognized cause; nevertheless, other bacteria, such as Enterobacteriaceae and Prevotella , have emerged as putative gastric cancer causative agents in recent investigations. In addition, SCFAs, particularly butyrate, produced in the gut are known to modulate immune functions by enhancing the cytotoxic activity of CD8+ T cells and preventing gastric cancer, possibly via the GPR109A receptor. Although research on the cause–effect relationship between microbiota and gastric cancer is an emerging field, available data from human and animal studies suggest that the manipulation of the gut microbiota—through probiotics, diet, or specific treatments—may be useful in preventing and managing gastric cancer. This review discusses the role of gut microbiota and SCFAs in the diagnosis and therapy of gastric cancer, with a focus on their effective application in gastric cancer treatment.